HeartBeam 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Rob Eno

최고 경영자

US$2.6m

총 보상

CEO 급여 비율	13.5%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	1.4yrs

최근 관리 업데이트

Recent updates

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

Sep 28

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Sep 15

HeartBeam GAAP EPS of $0.43 beats by $0.70

Aug 11

HeartBeam: Cardiovascular Diagnostics On The Go

Dec 14

CEO 보상 분석

Rob Eno 의 보수는 HeartBeam 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$18m
Jun 30 2024	n/a	n/a	-US$17m
Mar 31 2024	n/a	n/a	-US$15m
Dec 31 2023	US$3m	US$345k	-US$15m

보상 대 시장: Rob 의 총 보상 ($USD 2.55M )은 US 시장( $USD 647.72K ).

보상과 수익: Rob 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Rob Eno

less than a year

테뉴어

US$2,552,204

보상

Mr. Robert P. Eno, also known as Rob, is Chief Executive Officer of HeartBeam, Inc. since October 21, 2024 and serves as its Chief Business Officer and was President from January 18, 2023 to October 21, 20...

리더십 팀

이름	위치	테뉴어	보상	소유권
Richard Ferrari	Executive Chairman	5.8yrs	US$238.59k	0.64% $ 477.5k
Robert Eno	CEO & Chief Business Officer	less than a year	US$2.55m	데이터 없음
Branislav Vajdic	Founder	less than a year	US$3.25m	3.42% $ 2.5m
Kenneth Persen	Chief Technology Officer	2.3yrs	US$1.41m	0% $ 0
Timothy Cruickshank	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Peter J. Fitzgerald	Member of Scientific Advisory Board & Chief Medical Officer	2.1yrs	데이터 없음	데이터 없음
Richa Gujarati	Senior Vice President of Product	1.2yrs	데이터 없음	데이터 없음

0.7yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 관리: BEAT 의 관리팀은 경험 (평균 재직 기간 0.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Richard Ferrari	Executive Chairman	5.8yrs	US$238.59k	0.64% $ 477.5k
Branislav Vajdic	Founder	no data	US$3.25m	3.42% $ 2.5m
Peter J. Fitzgerald	Member of Scientific Advisory Board & Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Mark Strome	Independent Director	1.4yrs	US$104.72k	1.03% $ 764.4k
George De Urioste	Independent Director	no data	US$152.50k	0.090% $ 66.9k
Michael Jaff	Independent Director	1.3yrs	US$148.65k	0.052% $ 39.0k
Willem Elfrink	Independent Director	no data	US$140.64k	1.47% $ 1.1m
Robert Harrington	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Marga Ortigas-Wedekind	Independent Director	no data	US$140.00k	0.36% $ 267.6k
C. Gibson	Chairman of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음
Kenneth Nelson	Independent Director	1.4yrs	US$102.60k	0.35% $ 262.2k
Tony Das	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

1.4yrs

평균 재임 기간

66.5yo

평균 연령

경험이 풍부한 이사회: BEAT 의 이사회는 경험(평균 재직 기간 1.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

HeartBeam 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Heartbeam Announces Chief Executive Officer Changes, Effective October 21, 2024

HeartBeam, Inc. Appoints Timothy Cruickshank as Chief Financial Officer

HeartBeam, Inc., Annual General Meeting, Jun 12, 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

HeartBeam, Inc. Announces Retirement of Richard Brounstein as Chief Financial Officer

Recent updates

Heartbeam, Inc. Announces Positive Data from Two Studies At Prestigious American Heart Association Conference

New minor risk - Share price stability

HeartBeam, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Heartbeam Announces Chief Executive Officer Changes, Effective October 21, 2024

Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation

HeartBeam, Inc. Appoints Timothy Cruickshank as Chief Financial Officer

New major risk - Financial position

HeartBeam, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Price target decreased by 38% to US$5.00

HeartBeam, Inc. has filed a Follow-on Equity Offering in the amount of $17 million.

HeartBeam, Inc., Annual General Meeting, Jun 12, 2024

HeartBeam, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 38% to US$5.00

High number of new and inexperienced directors

HeartBeam, Inc. Presents Positive Results on its Artificial Intelligence Capabilities for Detecting Arrhythmias

New major risk - Revenue and earnings growth

High number of new and inexperienced directors

HeartBeam, Inc. Announces First Patients Enrolled in Pivotal Study Evaluating HeartBeam's AIMIGo System for Synthesizing A 12-Lead ECG

HeartBeam, Inc. Receives Two New US Patents for Its Core Cardiac Monitoring Technology

HeartBeam, Inc. to Report Q4, 2023 Results on Mar 20, 2024

HeartBeam, Inc. Announces Retirement of Richard Brounstein as Chief Financial Officer

HeartBeam, Inc. Unveils AI Program Designed to Deliver Unprecedented Personalized Cardiac Insights

HeartBeam, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Heartbeam, Inc. Appoints Richa Gujarati as Senior Vice President, Product

HeartBeam, Inc. Appoints Michael R. Jaff to the Board of Directors

Less than half of directors are independent

Heartbeam Appoints Ken Nelson and Mark Strome to the Board of Directors

HeartBeam, Inc., Annual General Meeting, Jul 07, 2023

HeartBeam, Inc. Announces Automated Cardiac Detection Patent Granted for Heartbeam Aimigo™ System

HeartBeam, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

HeartBeam, Inc. Appoints Robert Eno as President

Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky

HeartBeam Receives European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam, Inc. Announces Patent for 12-Lead Electrocardiogram Smartwatch-Based Monitor

Less than half of directors are independent

HeartBeam, Inc. to Report Q3, 2022 Results on Nov 10, 2022

HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

HeartBeam gets a new chief medical officer

HeartBeam Broadens Product Portfolio Pipeline with Smartwatch Connectivity Enablement for 24/7 Heart Monitoring Solution

Heartbeam Grants Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%

HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks

Heartbeam Announces FDA Submission of Heartbeam Aimi™ Product

Heartbeam, Inc. Announces Resignation of Alan Baumel as Chief Operating Officer, Effective on August 15, 2022

HeartBeam GAAP EPS of $0.43 beats by $0.70

HeartBeam, Inc. Announces the Appointment of Ken Persen to the Role of Chief Technology Officer

HeartBeam, Inc. to Report Q2, 2022 Results on Aug 11, 2022

HeartBeam, Inc., Annual General Meeting, Jun 15, 2022

No independent directors

HeartBeam, Inc. Announces Board Changes

HeartBeam: Cardiovascular Diagnostics On The Go

Director exercised options to buy US$1.4m worth of stock.

No independent directors

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령